The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue ...

The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will not ...

About Tenosynovial Giant Cell Tumor (TGCT) TGCT is a rare disease caused by a translocation in colony-stimulating factor 1 (CSF1) ...

Vimseltinib improved objective response rate compared with placebo for patients with tenosynovial giant cell tumor, according to topline data from the agent’s manufacturer. Safety results from ...

TURALIO ® Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of ENLIVEN Phase 3 Trial. Final long-term efficacy and ...

The FDA has approved vimseltinib, a new oral drug for a rare, noncancerous tumor of the joints known as tenosynovial giant cell tumor (TGCT). It is intended for adults with symptomatic TGCT when ...

U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT) ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue ...